Clinic
Dignity Health
Dignity Health was paid $106.54M by Medicaid between Jan 2018 and Dec 2024, across 401 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 30% of everything it billed.
33Billing provider infoDIGNITY HEALTH
MERCED, CA 95340
MERCED, CA 95340
33aNPI1518018191assigned 01/12/2007
33bProvider typeRural Health Clinic/Center
28Total paid$106.54M
24GClaims2,313,767
24DCodes billed401
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Health Clinic/Center providers in California
Rank by total paid#2 of 215
Median peer was paid$3.62M
This provider vs. median29×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 284,268 | $13.74M | |
| 2019 | 277,666 | $12.30M | |
| 2020 | 216,617 | $9.98M | |
| 2021 | 295,560 | $12.71M | |
| 2022 | 392,043 | $18.04M | |
| 2023 | 465,914 | $21.22M | |
| 2024incomplete | 381,699 | $18.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 30% | 171,465 | 156,496 | $31.69M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 18% | 237,370 | 218,845 | $19.54M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.8% | 138,891 | 119,630 | $4.00M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 11,945 | 11,611 | $2.78M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 48,801 | 45,493 | $2.18M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.8% | 63,304 | 56,519 | $1.93M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 23,322 | 21,889 | $1.89M |
| 80053 | Comprehensive metabolic panel | 1.7% | 139,331 | 126,360 | $1.82M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 6,337 | 6,205 | $1.78M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 16,676 | 15,694 | $1.44M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 29,162 | 23,246 | $1.31M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.2% | 887 | 886 | $1.29M |
389 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 134,748 | $1.27M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 8,156 | $1.18M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 11,290 | $1.15M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 19,278 | $1.10M |
| 0450 | Emergency room services | 1.0% | 9,868 | $1.08M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 10,785 | $1.06M |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,247 | $740K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 24,618 | $709K |
| 84484 | <1% | 42,595 | $690K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,004 | $680K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 6,583 | $607K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,043 | $571K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,479 | $562K |
| 83880 | <1% | 17,153 | $534K | |
| 59425 | <1% | 5,947 | $533K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 174,173 | $462K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14,207 | $462K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,286 | $430K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 110 | $418K |
| 97799 | <1% | 9,243 | $383K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,518 | $379K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,947 | $362K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,711 | $339K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,079 | $333K |
| Z7502 | <1% | 8,683 | $328K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,281 | $315K |
| 71045 | Radiologic examination, chest; single view | <1% | 23,638 | $315K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 411 | $315K |
| 83690 | <1% | 36,294 | $313K | |
| 82553 | <1% | 24,309 | $311K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,408 | $305K |
| 81025 | <1% | 29,085 | $293K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21,912 | $285K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 690 | $284K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,621 | $282K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,834 | $276K |
| 93971 | <1% | 1,601 | $267K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,477 | $266K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,928 | $265K |
| 99205 | Prolong outpt/office vis | <1% | 2,249 | $264K |
| 70486 | <1% | 959 | $263K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,792 | $261K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 4,806 | $255K |
| 87040 | <1% | 11,879 | $238K | |
| 81001 | <1% | 55,948 | $227K | |
| 93976 | <1% | 700 | $223K | |
| 86803 | <1% | 11,903 | $219K | |
| 86703 | <1% | 12,138 | $214K | |
| 76801 | <1% | 2,544 | $212K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 22,899 | $210K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 825 | $209K |
| 82550 | <1% | 29,342 | $207K | |
| 70496 | <1% | 778 | $204K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,198 | $198K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 2,590 | $194K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 9,927 | $190K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,161 | $186K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 1,925 | $184K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,166 | $178K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,302 | $177K |
| 96367 | <1% | 4,039 | $176K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,267 | $176K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 255 | $172K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 2,696 | $168K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 123 | $159K |
| 83605 | <1% | 10,800 | $154K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,764 | $152K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,152 | $150K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,122 | $149K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,325 | $146K |
| 71250 | <1% | 532 | $142K | |
| 97165 | <1% | 1,610 | $140K | |
| 76770 | <1% | 1,234 | $136K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,606 | $135K |
| Z9725 | <1% | 3,078 | $132K | |
| 92551 | <1% | 6,812 | $126K | |
| 72131 | <1% | 443 | $124K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,227 | $121K |
| 85730 | <1% | 17,774 | $118K | |
| 90686 | <1% | 6,882 | $112K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,699 | $112K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,158 | $111K |
| 90715 | <1% | 2,778 | $110K | |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 49 | $110K |
| 70498 | <1% | 775 | $108K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,144 | $106K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,488 | $105K |
| 72100 | <1% | 2,247 | $102K | |
| 84702 | <1% | 4,993 | $100K | |
| 99199 | Unlisted special service, procedure or report | <1% | 1,903 | $99K |
| J3490 | Unclassified drugs | <1% | 6,149 | $99K |
| 73221 | <1% | 146 | $99K | |
| 72141 | <1% | 118 | $97K | |
| 99243 | <1% | 1,025 | $93K | |
| 85610 | <1% | 20,197 | $92K | |
| 82962 | <1% | 31,494 | $91K | |
| 80061 | Lipid panel | <1% | 5,427 | $89K |
| 93970 | <1% | 346 | $89K | |
| 76641 | <1% | 823 | $89K | |
| 73030 | <1% | 2,261 | $88K | |
| 74178 | <1% | 256 | $88K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,520 | $86K |
| 87186 | <1% | 5,154 | $84K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 500 | $84K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,440 | $83K |
| 73130 | <1% | 2,071 | $82K | |
| 29880 | <1% | 53 | $80K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,866 | $80K |
| 73562 | <1% | 2,164 | $77K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 981 | $76K |
| 85027 | <1% | 9,192 | $76K | |
| 86592 | <1% | 13,547 | $75K | |
| 73610 | <1% | 1,746 | $73K | |
| 73630 | <1% | 1,822 | $72K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 764 | $69K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 366 | $68K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,663 | $68K |
| 87077 | <1% | 4,866 | $67K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,113 | $67K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,793 | $67K |
| 86141 | <1% | 4,327 | $66K | |
| 81003 | <1% | 22,262 | $65K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,971 | $64K |
| 96417 | <1% | 1,490 | $64K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 199 | $62K |
| 99284 | Emergency room visit (serious) | <1% | 745 | $61K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,985 | $61K |
| 99283 | Emergency room visit (moderate) | <1% | 592 | $61K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 126 | $61K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,351 | $55K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,500 | $51K |
| 76870 | <1% | 524 | $50K | |
| 84439 | <1% | 4,083 | $50K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,493 | $50K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,038 | $50K |
| 82803 | <1% | 1,621 | $49K | |
| 90651 | <1% | 1,474 | $48K | |
| 59025 | Fetal non-stress test | <1% | 913 | $48K |
| 73110 | <1% | 1,179 | $46K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,140 | $46K |
| 84466 | <1% | 2,484 | $43K | |
| 72040 | <1% | 1,041 | $43K | |
| 73502 | <1% | 950 | $42K | |
| 86850 | <1% | 3,379 | $42K | |
| 97014 | <1% | 1,958 | $40K | |
| 99285 | Emergency room visit (most serious) | <1% | 267 | $40K |
| 82248 | <1% | 6,178 | $40K | |
| 74018 | <1% | 1,355 | $40K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 403 | $39K |
| 90670 | <1% | 1,736 | $38K | |
| 71101 | <1% | 535 | $38K | |
| 77066 | Tomosynthesis, mammo | <1% | 212 | $37K |
| 96415 | <1% | 1,314 | $36K | |
| 82728 | <1% | 1,954 | $36K | |
| 99152 | <1% | 484 | $35K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 220 | $34K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,998 | $34K |
| 82150 | <1% | 4,015 | $34K | |
| 87631 | <1% | 385 | $33K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 405 | $33K |
| 73080 | <1% | 754 | $32K | |
| 76536 | <1% | 393 | $32K | |
| 82805 | <1% | 463 | $29K | |
| 99173 | <1% | 5,092 | $29K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 20,795 | $29K |
| 84703 | <1% | 2,831 | $29K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,188 | $29K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 48 | $28K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 287 | $28K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 295 | $27K |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,431 | $25K |
| 83735 | <1% | 3,182 | $25K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 845 | $24K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 178 | $24K |
| 85007 | <1% | 5,137 | $24K | |
| 83540 | <1% | 2,637 | $23K | |
| 90723 | <1% | 1,508 | $23K | |
| 86901 | <1% | 5,457 | $22K | |
| 90677 | <1% | 353 | $21K | |
| 85379 | <1% | 1,750 | $21K | |
| 87081 | <1% | 2,154 | $21K | |
| 82378 | <1% | 842 | $21K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,601 | $20K |
| 90647 | <1% | 1,347 | $20K | |
| 90633 | <1% | 1,313 | $20K | |
| 77386 | <1% | 90 | $20K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,083 | $20K |
| 86900 | <1% | 4,986 | $19K | |
| 77085 | <1% | 309 | $19K | |
| 84145 | <1% | 711 | $19K | |
| 82010 | <1% | 1,848 | $19K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 512 | $19K |
| 87522 | Neg quan hep c or qual rna | <1% | 521 | $18K |
| 87070 | <1% | 1,462 | $18K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,315 | $18K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,920 | $18K |
| 11721 | <1% | 3,387 | $18K | |
| 73590 | <1% | 569 | $18K | |
| 81002 | <1% | 11,314 | $18K | |
| 80164 | <1% | 945 | $17K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 499 | $17K |
| 80305 | <1% | 1,922 | $17K | |
| 82746 | <1% | 842 | $17K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 69 | $17K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,739 | $15K |
| 70491 | <1% | 46 | $14K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 428 | $13K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 17 | $13K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 436 | $12K |
| 73090 | <1% | 411 | $12K | |
| 90680 | <1% | 835 | $12K | |
| 94729 | <1% | 193 | $12K | |
| 82140 | <1% | 758 | $12K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 45 | $12K |
| 73560 | <1% | 450 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,470 | $12K |
| 96368 | <1% | 403 | $11K | |
| 93458 | <1% | 13 | $11K | |
| 74019 | <1% | 317 | $11K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 105 | $11K |
| 94060 | <1% | 229 | $11K | |
| 77334 | <1% | 55 | $10K | |
| 90734 | <1% | 563 | $10K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 445 | $10K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 102 | $9K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 12 | $9K |
| 72072 | <1% | 160 | $9K | |
| 93798 | <1% | 359 | $9K | |
| 90710 | <1% | 457 | $9K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 426 | $8K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 871 | $8K |
| 96523 | <1% | 399 | $8K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 493 | $7K |
| 90733 | <1% | 61 | $7K | |
| 73140 | <1% | 280 | $7K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 443 | $7K |
| 90750 | <1% | 43 | $7K | |
| 78227 | <1% | 13 | $7K | |
| 72110 | <1% | 102 | $7K | |
| 84100 | <1% | 1,352 | $7K | |
| 82043 | <1% | 875 | $7K | |
| 86300 | <1% | 313 | $7K | |
| 82607 | <1% | 428 | $7K | |
| 85652 | <1% | 1,924 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 601 | $7K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 625 | $6K |
| 86780 | <1% | 708 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 977 | $6K |
| 85014 | <1% | 2,975 | $6K | |
| 96411 | <1% | 215 | $6K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 256 | $6K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 249 | $6K |
| 90696 | <1% | 347 | $5K | |
| 96416 | <1% | 72 | $5K | |
| 90716 | <1% | 264 | $5K | |
| 94726 | <1% | 85 | $5K | |
| 90707 | <1% | 236 | $5K | |
| 76642 | <1% | 51 | $5K | |
| 70487 | <1% | 12 | $5K | |
| 97162 | <1% | 302 | $5K | |
| 73564 | <1% | 104 | $5K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 14 | $4K |
| 0270 | <1% | 4,897 | $4K | |
| 73120 | <1% | 172 | $4K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 55 | $4K |
| 90620 | <1% | 198 | $4K | |
| 83615 | <1% | 507 | $4K | |
| 99384 | <1% | 33 | $4K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 13 | $4K |
| 97116 | <1% | 197 | $4K | |
| Z7610 | <1% | 1,326 | $4K | |
| 84550 | <1% | 638 | $4K | |
| 11720 | <1% | 446 | $4K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 436 | $4K |
| 94644 | <1% | 127 | $4K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 99 | $4K |
| 83655 | <1% | 287 | $4K | |
| 99383 | <1% | 35 | $3K | |
| 82570 | <1% | 455 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,443 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 476 | $3K |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 1,634 | $3K |
| 77080 | <1% | 70 | $3K | |
| V2632 | Posterior chamber intraocular lens | <1% | 31 | $3K |
| 90656 | <1% | 187 | $3K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 145 | $3K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 987 | $3K |
| 59430 | <1% | 29 | $3K | |
| 80074 | <1% | 55 | $3K | |
| 77336 | <1% | 41 | $3K | |
| 92523 | <1% | 14 | $3K | |
| 82247 | <1% | 331 | $2K | |
| 0250 | <1% | 727 | $2K | |
| 72192 | <1% | 15 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 56 | $2K |
| 71271 | <1% | 13 | $2K | |
| 71020 | <1% | 68 | $2K | |
| 94727 | <1% | 55 | $2K | |
| 87340 | <1% | 347 | $2K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 220 | $2K |
| 90700 | <1% | 146 | $2K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 40 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 225 | $2K |
| 73600 | <1% | 70 | $2K | |
| 72128 | <1% | 12 | $2K | |
| 87149 | <1% | 88 | $2K | |
| 74220 | <1% | 39 | $2K | |
| 11056 | <1% | 337 | $2K | |
| 73100 | <1% | 67 | $2K | |
| 73620 | <1% | 68 | $2K | |
| 90685 | <1% | 107 | $2K | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 139 | $2K |
| 77065 | Tomosynthesis, mammo | <1% | 13 | $2K |
| 95816 | <1% | 25 | $2K | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 174 | $2K |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 14 | $2K |
| 87634 | <1% | 17 | $2K | |
| 86480 | <1% | 52 | $1K | |
| 97750 | <1% | 26 | $1K | |
| 84156 | <1% | 256 | $1K | |
| 0760 | <1% | 46 | $1K | |
| 11055 | <1% | 159 | $1K | |
| A9150 | Non-prescription drugs | <1% | 2,148 | $1K |
| 85018 | <1% | 571 | $967.38 | |
| 99386 | <1% | 12 | $934.48 | |
| 82105 | <1% | 37 | $931.02 | |
| 85045 | <1% | 157 | $880.86 | |
| 73552 | <1% | 31 | $867.53 | |
| 73060 | <1% | 28 | $852.73 | |
| 87205 | <1% | 132 | $768.68 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 29 | $766.17 |
| 76881 | <1% | 15 | $736.51 | |
| 86334 | <1% | 53 | $705.00 | |
| 96379 | <1% | 4,880 | $683.75 | |
| 84153 | <1% | 39 | $682.09 | |
| 97161 | <1% | 28 | $672.61 | |
| 86580 | <1% | 168 | $609.47 | |
| 87420 | <1% | 30 | $538.02 | |
| 85384 | <1% | 40 | $534.59 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 70 | $527.49 |
| 17110 | <1% | 68 | $485.20 | |
| 86593 | <1% | 102 | $453.35 | |
| Z7500 | <1% | 13 | $443.30 | |
| 82274 | <1% | 21 | $424.83 | |
| 86920 | <1% | 14 | $419.10 | |
| 87147 | <1% | 50 | $415.74 | |
| 87493 | <1% | 277 | $412.80 | |
| 73070 | <1% | 13 | $401.35 | |
| 20610 | <1% | 59 | $376.82 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 43 | $350.92 |
| 73000 | <1% | 13 | $344.89 | |
| 72170 | <1% | 12 | $335.49 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 14 | $299.29 |
| 82375 | <1% | 15 | $286.00 | |
| 87210 | <1% | 34 | $283.54 | |
| 80076 | <1% | 26 | $282.52 | |
| 86706 | <1% | 18 | $243.36 | |
| 86038 | <1% | 14 | $203.60 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 36 | $200.21 |
| 84165 | <1% | 43 | $195.00 | |
| 0001A | <1% | 13 | $194.83 | |
| 86702 | <1% | 12 | $182.57 | |
| 86039 | <1% | 16 | $160.00 | |
| 96376 | <1% | 540 | $156.29 | |
| 76882 | <1% | 12 | $155.07 | |
| 82009 | <1% | 31 | $149.21 | |
| 86701 | <1% | 12 | $122.51 | |
| 99070 | <1% | 54 | $115.80 | |
| 83521 | <1% | 13 | $113.48 | |
| 82272 | <1% | 42 | $98.21 | |
| 80177 | <1% | 14 | $96.00 | |
| 86762 | <1% | 12 | $84.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,836 | $65.17 |
| 11057 | <1% | 15 | $58.28 | |
| 81000 | <1% | 14 | $29.49 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,443 | $21.09 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 139 | $13.32 |
| J2704 | Injection, propofol, 10 mg | <1% | 13 | $12.17 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 26 | $5.25 |
| 94760 | <1% | 781 | $1.95 | |
| Z1034 | 0% | 984 | $0.00 | |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | 0% | 39 | $0.00 |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 14 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 22 | $0.00 |
| Z6400 | 0% | 14 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 33 | $0.00 |
| 90653 | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.